Skip Navigation
Skip Website Tools

Contact Info

H. Clifford Lane, M.D.
Building 10, Room 4-1479
10 Center Drive
Bethesda, MD 20892-1460
Phone: 301-496-7196
Fax: 301-480-5560
clane@niaid.nih.gov​

Laboratory of Immunoregulation

Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

H. Clifford Lane, M.D.

Photo of Dr. H. Clifford Lane

Clinical Director, NIAID
Chief, Clinical and Molecular Retrovirology Section, LIR

Major Areas of Research

  • Pathogenesis of HIV infection emphasizing mechanisms of immunodeficiency
  • Immunologic approaches to therapy for HIV infection
 

Biography

Dr. Lane received his M.D. from the University of Michigan in 1976. He then completed an internship and residency at the University of Michigan Hospital, Ann Arbor. In 1979, Dr. Lane came to the National Institutes of Health as a clinical associate in the Laboratory of Immunoregulation (LIR). In 1985, he was appointed deputy clinical director of NIAID; in 1989, he became the chief of the Clinical and Molecular Retrovirology Section of LIR, a position he still holds. In 1991, Dr. Lane became clinical director of NIAID and, in 2006, became NIAID Deputy Director for Clinical Research and Special Projects. He is currently on the editorial boards of the Journal of Acquired Immune Deficiency Syndromes and The American Journal of Medicine.

Selected Publications

Imamichi H, Lane HC. Regulatory T cells in HIV-1 infection: the good, the bad, and the ugly. J Infect Dis. 2012 May;205(10):1479-82.

Ledwaba L, Tavel JA, Khabo P, Maja P, Qin J, Sangweni P, Liu X, Follmann D, Metcalf JA, Orsega S, Baseler B, Neaton JD, Lane HC; Project Phidisa Biomarkers Team. Pre-ART levels of inflammation and coagulation markers are strong predictors of death in a South African cohort with advanced HIV disease. PLoS One. 2012;7(3):e24243. 

Sneller MC, Kopp WC, Engelke KJ, Yovandich JL, Creekmore SP, Waldmann TA, Lane HC. IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood. Blood. 2011 Dec 22;118(26):6845-8.

Lane HC. Pathogenesis of HIV infection: total CD4+ T-cell pool, immune activation, and inflammation. Top HIV Med. 2010 Feb-Mar;18(1):2-6. 

Visit PubMed for a complete publication listing.

Patents

Lane HC, Kovacs JA, Fauci AS, inventors; The United States of America as represented by the Department of Health and Human Services, assignee. Immunologic enhancement with intermittent interleukin-2 therapy. United States patent US 6,548,055. 15 Apr 2003.

Lane HC, Kovacs JA, Fauci AS, inventors; The United States of America as represented by the Department of Health and Human Services, assignee. Immunologic enhancement with intermittent interleukin-2 therapy. United States patent US 6,190,656. 20 Feb 2001.

Lane HC, Kovacs JA, Fauci AS, inventors; The United States of America as represented by the Department of Health and Human Services, assignee. Immunologic enhancement with intermittent interleukin-2 therapy. United States patent US 5,696,079. 9 Dec 1997.

Lane HC, Kovacs JA, inventors; The United States of America as represented by the Department of Health and Human Services, assignee. Immunologic enhancement with intermittent interleukin-2 therapy. United States patent US 5,419,900. 30 May 1995.

Last Updated September 05, 2012

Last Reviewed September 05, 2012